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Abstract
Background: The objectives of this study were to describe hospital stays related to HZ and to evaluate the direct
and indirect cost of hospitalizations due to HZ among patients aged over 50 years.
Methods: The hospitalizations of people aged over 50 years were selected from the French national hospital 2011
database (PMSI) using ICD-10 diagnosis codes for HZ.
Firstly, stays with HZ as principal or related diagnostic were described through the patient characteristics, type of
hospitalization and the related costs. Secondly, a retrospective case–control analysis was performed on stays with
HZ as comorbidity in 5 main hospitalizations causes (circulatory, respiratory, osteo-articular, digestive systems and
diabetes) to assess the impact of HZ as co-morbidity on the length of stay, mortality rate and costs.
Results: In the first analysis, 2,571 hospital stays were collected (60 % of women, mean age: 76.3 years and mean
LOS: 9.5 days). The total health assurance costs were 10,8 M€. Mean cost per hospital stay was 4,206€. In the second
analysis, a significant difference in LOS and costs was shown when HZ was associated as comorbidity in other
hospitalization’s causes.
Conclusions: HZ directly impacts on the hospital cost. When present as comorbidity for other medical reasons, HZ
significantly increases the length of hospital stay with subsequent economic burden for the French Health System.
Keywords: Herpes Zoster, Direct cost, Hospitalization, French, Indirect cost
Background
Herpes zoster (HZ), also called “shingles,” results from
reactivation of latent varicella-zoster virus (VZV), after a
primo-infection known as “varicella” or “chickenpox”. It
spreads from a single ganglion to the neural tissue of the
affected segment and the corresponding cutaneous
dermatome [1].
If the reactivation is not contained, as can occur with
age-related immunosenescence or iatrogenic immuno-
suppression, then viral replication ensues, resulting in
ganglionitis, extensive infection, destruction of neurons
and supporting cells [2]. This significant infection and
associated inflammatory response is probably the origin
of the prodromal pain that precedes the characteristic
dermatomal eruption of HZ. Approximately 70 %–80 %
of patients with HZ describe prodromal pain in the
dermatome where skin lesions subsequently appear. Pro-
dromal pain may be constant or intermittent and fre-
quent or sporadic, and it may or may not interfere with
sleep. The rash associated with HZ has a brief erythema-
tous and macular phase, which is often missed, after
which papules rapidly appear. These papules develop
into vesicles within 1–2 days, and vesicles continue to
appear for 3–4 days [1].
Increasing age is the primary risk factor for herpes
zoster. The disease usually occurs after 50 years of age,
and approximately 60 percent of cases occur in women
[3, 4].Other risk factors include human immunodefi-
ciency virus infection, neoplasic diseases, organ trans-
plantation, use of immunosuppressive drugs, and other
conditions that cause a decline in cell-mediated immun-
ity. Complications occur in almost 50 % of older persons
(60 years of age or older) with HZ [5–7]. Most frequent
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complications are persistent and neurological pain, named
post-herpetic neuralgia (PHN), which concern 18 % of
adults with herpes zoster and 33 % of those aged 79 and
olders [8].
Herpes zoster ophthalmicus designates a localisation
of herpes zoster with eye's involvement. Eyes complica-
tions are common in this case and result in considerable
health care use and permanent vision decrement in
about 6.6 % of individual with HZ eyes involvement [9].
Throughout Europe, estimated annual HZ incidences
range from 2.0 to 4.6/1,000 person-years (PY) with lower
values in Iceland, Germany and Switzerland (around 2/
1,000 PY) and higher in Belgium, Spain, Italy (around 4/
1,000 PY) and globally concerning women. The inci-
dence and severity of HZ increase with advancing age;
more than half of all persons in whom HZ develops are
older than 60 years [10–14]. HZ epidemiological data are
annually estimated by the French sentinel surveillance
reporting system (based on data derived from consulta-
tions of a sample of French GPs). Moreover, HZ can be a
repetitive history: in contrast with previous assessments,
rates of HZ recurrence appear to be comparable to rates
of first occurrence in immunocompetent individuals [15].
In France, estimated HZ annual incidences were 346,988
cases in 2009 [16], 269,833 cases in 2010 [17], 219,823
cases in 2011 [18] and 303,625 cases in 2012 [19]. Based
on the sentinel surveillance reporting system, Gonzalez
Chiappe et al., estimated the French 2010 HZ incidence
rate to be 382 cases/100,000 inhabitants. The article also
studies herpes zoster hospitalizations trough the PMSI
database between 2000 and 2006. Over the seven years,
61,429 hospital stays were collected with a mean annual of
8,728 stays per year. The mean age observed was 72 years
and mean LOS was 9.18 days [20].
The objectives of this study were to describe hospital
stays related to HZ in 2011, and to evaluate the cost of
hospitalizations due to HZ and the impact of zona as
comorbidity on length of stay, death and cost in




The French Medical Information System (Programme de
Médicalisation des Systèmes d'Information – PMSI) is an
exhaustive medico-administrative hospital discharge data-
base that covers all public and private hospitals in France
as well as those in the French Territories [21–26]. Diagno-
ses identified during admission are coded using the
International Classification of Diseases, 10th revision
(ICD-10) by the physician. PMSI includes a compilation
of standard discharge summaries (“Résumé Standard de
Sortie”, RSS) for every admission. Anonymised data
(“Résumé Standardisé Anonymisé”, RSA) with limited
socio-demographic information (gender, age, residence
code) and medical information on the main diagnosis
that led to hospital admission, the nature of treatments
received and examinations carried out, underlying co-
morbidities and possible complications, are made avail-
able for epidemiologic studies. Each patient's stay is
classified by Diagnosis Related Group (DRG) (Groupe
Homogène de Séjours) according to the information
documented by the physician.
The economic burden of hospitalized cases would be
expected to be well documented within the PMSI
database because since the introduction of a DRG-
based prospective payment system (the “Tarification à
l’Activité”) in 2005, the PMSI database has been used
as the basis for the funding of services in all hospitals,
with each hospital receiving DRG-based payments ac-
cording to the national tariff. Thus, data extracted
from this database is exhaustive (all public and private
hospitals are included and no sampling is done) and of
high quality, with limited coding errors.
Data collection of herpes zoster
All hospital stays with a primary, related and associated
herpes zoster specific code were selected from the 2011
PMSI database using the ICD-10 codes B02* (“Zoster)”.
In order to evaluate the hospitalization economic impact
of HZ among patients aged over 50 years in France and
to assess the impact on death, hospitalization’s length of
stay and hospitalization’s cost of HZ when this latter is
comorbidity in other hospitalization’s causes, two differ-
ent data collection were done from the PMSI database.
For the first analysis, a conservative approach was
done by selecting only those hospital stays that had a
primary diagnosis or had direct link with HZ for pa-
tients aged over 50 years. HZ ICD 10 codes were
selected based on Gonzalez Chiappe et al. in 2010 pub-
lication, by seven codes: B020 “HZ encephalitis”, B021
”HZ meningitis”, B022 ”HZ with neurological disease”,
B023 ”HZ Ophthalmicus”, B027 ”Disseminated HZ”,
B028 ”HZ with other complications” and B029 ”HZ
with no complications” [20]. A physician manually
assessed all hospital stay cases that have an associated
link to HZ (i.e. where HZ was a secondary diagnosis)
to exclude those where HZ was considered doubtful.
For patient’s hospitalized for HZ, gender, age and
comorbidities, type of management received (medical,
surgical or exploratory), type of stay (conventional in-
patient stays or short outpatient stays), and length of
stay, type of HZ, immunosuppression factors, hospital
discharges and occurrence of related deaths were col-
lected. Conventional inpatient stays include day hospital-
izations defined as an admission of 2 or more days’
duration, whereas short stays include day hospitaliza-
tions. Since patients may have several hospital stays
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during the year, the overall number of patients hospital-
ized at least once over a given period could be obtained
by linking all hospital stays with anonymized patient
identification numbers based on the patient’s social se-
curity number, date of birth and gender.
For the second analysis, all hospital stays with an associ-
ated HZ diagnosis code were firstly selected. Then im-
munocompromised patients have been excluded. Codes of
immunosuppressive conditions were D8* “Certain disor-
ders involving the immune mechanism“; B20* ”Human
immunodeficiency virus [HIV] disease resulting in infec-
tious and parasitic diseases“ to B24* “Unspecified human
immunodeficiency virus [HIV] disease”. A disease ap-
proach was done by selecting only all the hospital stays in
5 main diseases where HZ is only a comorbidity diagnosis
and not the reason for hospitalization. The first five
reasons of hospitalizations observed with a HZ comorbid-
ity were hospitalizations for circulatory system (14 %),
hospitalizations for respiratory system (11 %), hospitaliza-
tions for osteo-articular system (6 %), hospitalizations for
digestive systems (6 %) and hospitalizations for diabetes
system (2 %).
For patients hospitalized for the 5 main diseases with
HZ comorbidity, gender, age, were collected. A retro-
spective case–control was performed for each of the pre-
selected 5 pathologies excluding hospital stays with at
least an immunosuppression diagnosis. The cases were
defined by hospitalizations with HZ in DAS and controls
by cases-matched hospitalizations without HZ in DAS.
Chi-square tests were done to compare the distribution
of both genders and age between the two cohorts. A
matching method based on age and sex was performed to
neutralize confounding factors. Then median LOS, hos-
pital mortality and costs were calculated for both selec-
tions and compared by statistical non-parametric analyses
(Wilcoxon-Mann-Whitney) in each of the five categories.
Economic burden of HZ hospitalization
Costs were estimated from the social security payer
perspective, i.e. Ministry of Health public fund. Ambu-
latory costs and indirect costs related to productivity
loss were not considered in the present study. Hospital-
associated costs were calculated using official DRG
tariffs for each year considered. DRG tariffs represent
the willingness-to-pay by the national health insurance
and not the hospital cost production. DRG tariffs in-
clude medical and related procedures, nursing care,
treatments (except specific expensive drugs), food and
accommodation, and investment costs for hospitalized
patients. Additional cost per day of hospitalization in
emergency or an intensive care unit was added to DRG
tariffs, when appropriate. For private hospitals, physi-
cian’s fees were also added to the DRG tariffs; physi-
cians are reimbursed on a fee-for-service basis [source:
ENCC 2010]. Costs are presented as mean/median cost
per stay, mean/median cost per patient and total cost
per year for France. All costs are presented in actual-
ized Euros (base year 2012).
Ethics and consent
This non-interventional study does not fall under the scope
of the law and does not require any ethics committee sub-
mission (Law 88–1138 relative to Biomedical Research of
December 20, 1988, modified on August 9, 2004). The
ATIH (Agence Technique de l’Information sur l’Hospitalisa-
tion) is responsible for managing the finalized database each
year under approval by the CNIL (National commission for
data processing and civil liberties).
Results
Burden of HZ hospitalization
Hospital stay characteristics
A total number of 7,389 stays for HZ were identified in
the PMSI 2011 database for patients aged over 50 years.
A medical interpretation by a DIM physician classified
the selection into 2 groups, 2,571 hospital stays (35 %),
related to 2,392 patients, were directly related to HZ
(2,362 and 209 stays were in public and private hospitals,
respectively), and 4,818 stays (65 %) were indirectly re-
lated to HZ. This last group was excluded (4,047 and
771 stays were in public and private hospitals, respect-
ively) [Fig. 1]. A conservative approach was taken by
selecting only those hospital stays that had a primary
diagnosis of HZ or had direct link with HZ.
Over the 2,571 hospital stays observed during the
study period for HZ, stays for B029 “HZ without com-
plications” was mainly represented with 911 hospital
stays (33.1 %). The following type of zona B023 “HZ
Ophthalmicus”, B028 “HZ with other complications”,
and B022 “HZ with neurological disease” represented
between 450 and 487 stays (17.5 % to 18.9 %). Others
type of zona represented between 147 and 44 hospital
stays [Table 1].
Sex ratios were equivalent in almost all HZ type.
Women represented 60 % of patients of the cases. We
observed a different sex ratio only in the B027 “Dis-
seminated HZ” type where the women represented
50 % of patients.
Over the 2,392 patients included, the overall mean age
was 76.3 years (SD 11.7) and the median age was 79 years
(range 57) [Table 2]. The mean age was different between
HZ types : 77.7 years (SD 11.1) for B028 “HZ with other
complications”, 77.3 years (SD 11.2) for B023 “HZ
Ophthalmicus”, 73.5 years (SD 12.1) for B027 “Dissemi-
nated HZ”, 73.3 years (SD 11.7) for B021 “HZ meningitis”
and 74.2 years (SD 12.2) for B020 “HZ encephalitis”. Over
the 2,392 patients, 444 patients (18.6 %) were aged 80–84
years, 438 patients (18.3 %) were aged 85–89 years, 339
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B029 ”HZ with no
complications
Total
Public hospital stays 59 42 407 463 136 417 838 2,362
Private hospital stays 4 2 43 24 11 52 73 209
Total stays 63 44 450 487 147 469 911 2,571
% stays 2.5 1.7 17.5 18.9 5.7 18.2 35.4 100
LOS 19.5 14.3 9.8 9.1 13.0 9.8 7.9 9.5
Mean Costs per stay in
public hospital
8,912 € 5,122 € 4,597 € 3,587 € 7,269 € 4,848 € 3,568 € 4,350 €
SD 6,847 € 3,143 € 3,138 € 2,112 € 25,889 € 2,592 € 3,219 € 6,963 €
Median Costs per stay
in public hospital
8,304 € 4,206 € 3,819 € 3,426 € 5,205 € 5,765 € 3,702 € 3,701 €
Range 38,302 € 15,461 € 20,375 € 13,334 € 302,233 € 21,434 € 77,402 € 302,645 €
Mean Costs per stay in
private hospital
8,605 € 3,662 € 3,139 € 2,139 € 2,187 € 2,442 € 2,471 € 2,677 €
SD 4,698 € 230 € 1,880 € 1,194 € 1,248 € 1,324 € 1,785 € 1,897 €
Median Costs per stay
in private hospital
6,455 € 3,662 € 2,414 € 2,367 € 2,519 € 2,519 € 3,219 € 2,519 €
Range 9,770 € 325 € 681 € 4,962 € 3,570 € 5,868 € 6,136 € 15,341 €
Mean Costs per stay 8,893 € 5,056 € 4,458 € 3,516 € 6,888 € 4,581 € 3,480 € 4,206 €
SD 6,703 € 3,084 € 3,069 € 2,098 € 24,932 € 2,595 € 3,142 € 6,711 €
Median Costs per stay 8,304 € 4,206 € 3,819 € 3,427 € 3,869 € 5,765 € 3,702 € 3,702 €
Range 38,032 € 15,461 € 20,375 € 13,334 € 302,484 € 21,434 € 77,402 € 302,646 €
Total Costs 560,284 € 222,465 € 2,006,179 € 1,697,544 € 1,007,870 € 2,148,890 € 3,167,679 € 10,810,911
€
Proportion of the total
HZ cost
5 % 2 % 19 % 16 % 9 % 20 % 29 % 100 %
HZ: Herpes Zoster, LOS: Length of stay, SD: Standard Deviation
Stays with B02* codes as 
PD/DR/SAD in France on 2011
N= 8 490 stays
Stays with B02* codes over 
people aged over 50 years
N= 7 389 stays (87%)
Stays of patient aged under 50 
years
N= 1 101 stays
Stays of patient excluded after a 
medical interpretation by a PMSI 
specialist for SAD only
N= 4 818 stays
HZ as cause of hospitalization
N = 2 571 stays (36%)
Fig. 1 Chart flow of study protocol of HZ as cause of hospitalization
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patients (14.2 %) were aged 75–79 years, and 244 patients
(10.2 %) were aged 70–74 years [Table 2]. Patients were
mainly hospitalized once (95 %) during the study period of
1 year.
Public hospital represented 92 % (2,362) of hospital stays
[Table 1] and in nearly all hospital stays (97 %; 2,250), the
illness was medically managed, with surgical intervention
recorded in <1 % (30) of stays. More than half of stays
(72 %; 1,859) had comorbidity. Circulatory system was the
main co-morbidity with 41.7 % (1,071), followed by endo-
crine system in 28.6 % (735), nervous system in 21.0 %
(539) and malignancies in 14.6 % (376). [Fig. 2] Diabetes,
kidney diseases and respiratory system co-morbidity rates
ranged from 10.8 % (278) to 12.5 % (321) and finally mus-
culoskeletal system occurred in 0.6 % (15). A patient may
have several comorbidities within a stay, so the sum of dif-
ferent kinds of comorbidity stays does not give the total
amount of stays. Of the 2,571 hospital stays, 81 (3.2 %) stays
presented immunosuppression treatments codes, ranging
from 0.0 % to 3.6 % except for the code B027.
Conventional inpatient stays represented 44 % (2,408
stays) of all hospital stays. The mean length of hospital
stays was 9.5 days (SD 11.22) and the median length of
stay was 7 days (range from 0 to 385 days), ranging
from 7.9 days (SD 7.46) for B029 “HZ without compli-
cations” to 19.5 days (SD 15.37) for B020 “HZ enceph-
alitis” [Table 1].
A death rate of 1.6 % (38 patients) was observed dur-
ing the study, range 0.5 % (5/911) for B029 “HZ with-
out complications” to 7.9 % (5/63) for B020 “HZ
encephalitis” [Table 3]. Over the 38 deaths observed,
only 1 death occurred among patients with no comor-
bidity although 37 deaths occurred among patients with
at least one comorbidity.
Discharge from hospital to home occurred in 2,060/
2,571 hospital stays (80.1 %) [Table 3]. Alternatively, 289
hospital stays (11.2 %) led to a transfer into another
health care institution (173 stays in a Recovery after care
and rehabilitation Center). Intra hospital transfer oc-
curred in 184 hospital stays (7.2 %) and led to an internal




















6 2 19 18 11 14 44 113 4.7
55–59
years
4 7 32 22 16 24 69 171 7.1
60–64
years
3 3 30 38 13 34 83 201 8.4
65–69
years
8 5 34 30 14 30 81 193 8.1
70–74
years
6 0 48 45 19 50 78 244 10.2
75–79
years
9 7 64 75 17 73 105 339 14.2
80–84
years
11 8 84 91 23 88 146 444 18.6
85–89
years
12 8 75 84 25 83 161 438 18.3
90–94
years
3 1 30 45 6 44 67 190 7.9
95 years
and over
0 0 6 12 2 13 29 61 2.5
Total
(patients)




74.2 73.3 76.1 77.3 73.5 77.7 75.9 76.3




76,5 76 78 80 74 80 78 79
Range 43 39 52 57 47 52 51 57
HZ: Herpes Zoster, SD: Standard Deviation
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transfer between units within the same hospital. The rate
of discharge is very high for HZ except for the code B020
“HZ encephalitis” (31/63 stays or 49.2 %) and B021 “HZ
meningitis” (28/44 stays or 63.6 %) The latters have a
higher rate of transfer to another health care institution
with respectively 34.9 % for B020 and 22.7 % for B021
[Table 3].
Over the 2,571 stays, 2,446 hospital admissions (95 %)
from home patient were mainly observed. Among the
473 hospital discharges to transfer or mutation (289
transfers / 184 mutations), 419 hospital admissions (88 %)
from home patient were collected.
Economic burden of HZ hospitalization
Total HZ health insurance costs for the 2,571 hospital
stays were estimated at responsible for 10,810,911€
[Table 1]. The mean costs for health insurance per hos-
pital stay was 4,206€ (SD 6,211€) with a range from 4,350€
(SD 6,963€) for public hospital to 2,677€ (SD 1,897€) for
private hospital. The mean cost per patient was 4,519€
(SD 6,905€) range to 4,653€ (SD 7,164€) for public hos-
pital to 2,812€ (SD 1,888€) for private hospital.
The mean costs per hospital stay for HZ ranged from
8,893€ (SD 6,703€) for B020 “HZ encephalitis” to 3,480€
(SD 3,142€) for B029 “HZ without complications”
[Table 1]. The total annual costs of B029 “HZ without
complications” care were responsible for 29 % of total
HZ annual costs, B028 “HZ with other complications”
for 20 %, B022 “HZ with neurological disease” for 19 %,
B023 “HZ Ophthalmicus” for 16 %, B027 “Disseminated
HZ” for 9 %, B020 “HZ encephalitis” for 5 %, and B021
“HZ meningitis” for 2 % [Table 1].
Impact of HZ comorbidity in hospitalizations for other
reasons
Hospital stay characteristics
A total number of 4,818 hospital stays with a zona co-





MCO SSR USLD Total
Stay % Stay % Stay % Stay % Stay % Stay % Stay %
B020”HZ encephalitis” 31 49.2 % 9 40.9 % 12 54.5 % 1 4.5 % 22 34.9 % 5 7.9 % 5 7.9 % 63
B021 “HZ meningitis” 28 63.6 % 4 40.0 % 6 60.0 % 0 0.0 % 10 22.7 % 5 11.4 % 1 2.3 % 44
B022 “HZ with neurological disease” 356 79.1 % 14 29.8 % 31 66.0 % 2 4.3 % 47 10.4 % 39 8.7 % 8 1.8 % 450
B023 “HZ Ophtalmicus” 398 81.7 % 18 33.3 % 32 59.3 % 4 7.4 % 54 11.1 % 25 5.1 % 10 2.1 % 487
B027 “Disseminated HZ” 118 80.3 % 7 41.2 % 9 52.9 % 1 5.9 % 17 11.6 % 9 6.1 % 3 2.0 % 147
B028 “HZ with other complications” 372 79.3 % 18 35.3 % 32 62.7 % 1 2.0 % 51 10.9 % 40 8.5 % 6 1.3 % 469
B029 “HZ with no complications” 757 83.1 % 33 37.5 % 51 58.0 % 4 4.5 % 88 9.7 % 61 6.7 % 5 0.5 % 911
% Sub-Total 35.6 % 59.9 % 4.5 % 100 %
Total 2,060 80.1 % 103 4.0 % 173 6.7 % 13 0.5 % 289 11.2 % 184 7.2 % 38 1.5 % 2,571
HZ: Herpes Zoster, LOS: Length of Stay, MCO: Medicine Surgery Obstetrics, SSR: After-care and rehabilitation, USLD: Long-Term Care Unit
Fig. 2 Distribution of comorbidity in Zona hospital stays
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immunosuppression factors were identified in the 2011
PMSI database. Of the hospital stays with a zona comor-
bidity, only 1,717 hospital stays were selected corre-
sponding to the 5 main reasons of hospitalizations :
circulatory (ICD-10 codes: I0*-I5* & I7*-I9*), respiratory
(J0*-J9*), osteoarticular (M0*-M9*), digestive systems
(K0*-K9*), and diabetes (E1*). In order to evaluate the
statistical impact of zona as comorbidity on length of
stay, death rate, and cost, a separately case control was
performed for each disease.
Chi-square tests showed that age and sex distribution
were significantly different between the 2 cohorts for
each disease (p < 0.001). As a consequence, extracted
data were adjusted by age and sex for all disease
[Table 4]. A case-cohort stay was matched with 3 ran-
domly chosen control-cohort stays for the same age
group, sex and pathology. The co-morbidity analysis was
based on the selection of the 1.717 stays for patients
aged over 50 years in cases cohort and of 5,151 stays out
of the 3,665,088 stays of patients aged over 50 years in
control cohort [Table 4].
HZ impact as co-morbidity in 5 main diseases
In each of the five diseases, i.e. circulatory, respiratory,
osteoarticular system, digestive systems and diabetes, the
median LOS presented a statistically significant differ-
ence between cases and control cohorts [Table 5]. For
osteoarticular system, the median LOS differed by 3 days
leading to a 50 % rise from control cohort to cases
cohort. The median LOS differed by 4 days (+80 %) for
diabetes and by 5 days (+71 %) for respiratory system.
Then, the median LOS differed by 6 days for circulatory
system (+120 %) and for digestive system (+300 %).
Statistically significant difference in median stay costs
were demonstrated between cases and control cohorts
[Table 5]. For circulatory system, median stay costs dif-
fered by 857€ (25 % rise in the case cohort compared to
controls). Median stay costs differed by 922€ (+26 %),
from 945€ (+26 %) and from 987€ (+39 %) for osteoarti-
cular system, for respiratory system and for diabetes re-
spectively. Then, the median hospital stay costs differed
by 2,011€ for digestive system (+126 %).
No difference was observed in the death rates in 3 dis-
eases: circulatory system, respiratory system and diabetes
[Table 5]. Death rates for osteoarticular system varied
for the 3 age groups: it was identical in both cohorts of
[50-75] years groups; null in both cohorts of [75-85]
years groups and significantly different (1.86 % for cases
cohort and 0.24 % for control cohort) in the group of
85 years and over group.
Discussion
The current PMSI 2011 analysis identified 2,571 stays of
patients aged over 50 years hospitalized for HZ correspond-
ing of 0.9 % of the 2011 recorded total stays, while diabetes
represented 95,204 stays (62 times more) and degenerative
disease represented 48,291 stays (19 times more). The HZ
represents a subsequent economic burden of approximately
Table 4 Data classification per hospitalization causes, ages, and sex
Casesa Total Controlsb Total
[50–75] [75–85] [85 years
and over]
[50–75] [75–85] [85 years
and over]
Circulatory System Men 81 89 62 232 243 267 186 696
Women 57 133 193 383 171 399 579 1,149
Total 138 222 255 615 414 666 765 1,845
Respiratory System Men 86 89 73 248 258 267 219 744
Women 59 89 85 233 177 267 255 699
Total 145 178 158 481 435 534 474 1,443
Osteo-articular System Men 44 30 15 89 132 90 45 267
Women 62 51 66 179 186 153 198 537
Total 106 81 81 268 318 243 243 804
Digestive System Men 44 29 20 93 132 87 60 279
Women 71 64 47 182 213 192 141 546
Total 115 93 67 275 345 279 201 825
Diabetes Men 23 13 2 38 69 39 6 114
Women 8 20 12 40 24 60 36 120
Total 31 33 14 78 93 99 42 234
Total 535 607 575 1,717 1,605 1,821 1,725 5,151
aCohort of patients hospitalized with HZ as comorbidity
bCohort of patients hospitalized without HZ comorbidity
Blein et al. BMC Infectious Diseases  (2015) 15:350 Page 7 of 10
11 million€ in global Health Assurance expenses and qual-
ity management may reduce the total amount spent for HZ
treatment. The total annual costs of B029 “HZ without
complications” and B023 “Zoster Ocular Disease” care were
responsible for 29 % and 16 % of total HZ annual costs re-
spectively. The HZ stay mean cost is 4,206€ ranging be-
tween 3,480€ for HZ without complications to 8,893€ for
Zoster encephalitis. The Zoster Ocular Disease stay mean
cost of 3,516€ is similar to the cost observed in HZ without
complications. The absence of cost impact between these
two HZ is due to the classification DRG system. In the case
of Zoster Ocular Disease stays, the DRG are mainly dis-
tributed in the Major Diagnostic Category (MDC) 02
therefore the HZ without complications stays are mainly
distributed in the MDC 09. The DRG tariffs relevant to
the MDC 02 are lower than the DRG tariffs of MDC 09.
Clinical and costs input data were derived from a cohort
of 2,392 patients, with 60 % of women and with a mean
age of 76.3 years. Death occurs in 1.6 % of cases of pa-
tients hospitalized with zoster. B020 “HZ encephalitis”
and B021 “HZ meningitis” stays characteristics involved
older patients, longer LOS, higher rates of transfer to an-
other health care institution and higher death rates even
though the related number of extracted stays was the low-
est (63 and 44 stays respectively).
When present as only comorbidity in hospitalizations
for other hospitalization causes, HZ significantly increases
the LOS at hospital and subsequent economic burden for
the French health system whereas death rates were not
linear as expected and do not stand a classical conclusion.
Comorbidity indicates the co-occurrence of preexisting
age-related health conditions in reference to an index dis-
ease [27]. Advanced age is associated with increased
vulnerability to chronic health problems. Given the com-
plexity and heterogeneity involved in comorbidity, how-
ever, no single definition or measure would serve all
research and clinical purposes. The level of comorbidity
correlates with the magnitude of immune response in
older adults (decrease in T cell proliferation and IL-12
production and increase in IL-10 production in response
to PHA stimulation) [28]. Until recent published pa-
pers, comorbidities were not taken into account in the
management and prognosis of herpes zoster [29]. Risk
of herpes zoster has been found in patients with
chronic obstructive pulmonary disease [30], kidney
disease [31, 32], rheumatoid arthritis [33], inflamma-
tory bowel disease [34], type II diabetes [35]. In
addition, some authors report a risk of cancer after in-
fection by herpes zoster [36, 37]. Few data analyzed
impact of comorbidities on the management and the
cost of herpes zoster.
A Spanish study has been conducted by Gil-Prieto et al.
in 2011, describing the disease burden of patients aged
≥50 years hospitalized with HZ (in DP or DAS) between
Table 5 HZ as co-morbidity analyses: LOS, death rate and economic evaluation
Circulatory system Respiratory system Osteoarticulary system Digestive system Diabetes
LOS
Median (days) Casesa 11 12 9 8 9
Controlb 5 7 6 2 5
Median difference days 6 5 3 6 4
% rise 1.2 % 0.71 % 0.5 % 3 % 0.8 %
Tests (Wilcoxon-Mann–Whitney) (p values 0,05) <0.0100 <0.0001 <0.0001 <0.0001 <0.0001
Death rate
Deaths among cases cohorta
Death rate (%) 32/615 41/481 5/268 16/275 1/78
Deaths among control cohortb 5.2 % 8.52 % 1.86 % 5.81 % 1.28 %
Death rate (%) 113/1,845 155/1,443 2/804 26/825 3/234
Chi-square probability (p value 0,05) 6.12 % 10.74 % 0.24 % 3.15 % 1.28 %
Hospital stay cost
Median (€) Cases cohorta 4,228 4,534 4,475 3,601 3,510
Control cohortb 3,371 3,589 3,553 1,590 2,523
Median difference (€) 857 945 922 2,011 987
% rise 25 % 26 % 26 % 126 % 39 %
Tests (Wilcoxon-Mann–Whitney) (p value 0,05) <0.0100 <0.0001 <0.0001 <0.0001 <0.0001
HZ: Herpes Zoster
LOS: Length of stay
aCohort of patients hospitalized with HZ in SAD
bCohort of patients hospitalized without HZ in SAD
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1998 and 2004 who presented Chronic Obstructive Pul-
monary Disease (COPD), cardiovascular disease and/or dia-
betes [38]. The annual number of hospitalization was 2,289
stays with a mean LOS of 12.4 days. Death rates were 3.7 %
and increased to 4.7 % for patients with comorbidity even
though death rates were 2.1 % for the cohort without co-
morbidities. Death rates were higher due to a higher
death probability in the treatment of COPD, cardio-
vascular disease and/or diabetes as the cohort involved
patients hospitalized for another primary diagnosis
(COPD, cardiovascular disease and/or diabetes).
The study shows only than more women than men
with HZ are hospitalized and hospitalization is prevalent
in older ages, which is in line with epidemiological stud-
ies. As reported by Gonzalez Chiappe et al. [20] and by
Chang et al. two decades ago for an Asian population
[39], the predominance of HZ in women might be as-
cribed to a higher proportion of females in the older
population. Moreover, Thomas et al. added, in 2004, that
women might be more likely to seek medical advice,
thereby causing higher reporting rate [32]. Pinchinat et
al. review stated, in 2013, that HZ incidence increases
sharply with age for the European population [12, 40].
The present study method included a check step by
analyzing the age and sex characteristics and their statis-
tical differences in both groups with HZ and without
HZ in each of the five pathologies. This check step con-
clusion determined the need of matching for further
analyses to neutralize the confounding factors.
This study highlighted the impact of an associated
diagnosis of HZ for patients aged 50 years and older
with chronic conditions. When associated to one of
the 5 most common chronic diseases, HZ significantly
increased the LOS. Herpes Zoster significantly in-
creases length of hospitalization (p < 0.001) leading to
subsequent economic burden for the French health
system. It is expected that this extension of LOS also
has an impact on the cost of the management of the
disease. Herpes Zoster doesn’t significantly increase
the number of deaths.
This review has various limitations. First of all, PMSI
database is the basis of hospital funding and not an
epidemiological register. The prospective payment is dir-
ectly linked to the coding process leading to optimize
this latter. Nevertheless the high exhaustiveness and
quality of information (including some medical informa-
tion) allows using the PMSI database to estimate various
indicators by disease, like the number of patients hospi-
talized annually, the number of stays per patient and the
total cost of hospitalization [24–26]. Using hospitals
and death records generate limitations: codes were not
necessarily accurate; i.e., misclassification or diagnosis
errors by coding as a different herpes [41], under
reporting of pre-existing conditions such as stroke
[42]; inadvertent omissions, the unavailability of med-
ical records to certifying physician and difficulties in
determining the underlying cause of death and
hospitalization when several disease processes were
involved [43, 20].
Further investigations to study the impact of HZ comor-
bidty in other categories, to provide up-to-date analyses
(PMSI 2013 follow-up) in the following 5 to 10 years, will
allow a long-term projection of clinical characteristics,
economic evaluation and trend over time.
Conclusion
The present study evaluated the economic burden of
HZ as the cause of hospitalization and as comorbidity.
The total annual cost of HZ as cause of hospitalization
was approximately 11 millions € and the mean costs
per stay was 4,206€ (SD 6,711€). About a third (29 %)
of the annual cost was explained by the B029 “HZ with
no complications”.
When HZ was present as only comorbidity in five
hospitalizations reasons (circulatory system, respiratory
system, osteoarticular system, digestive system and dia-
betes), the hospitalizations length of stay and cost were
significantly increased (p < 0.001). Median stay costs
rose from 25 % to 126 % and median LOS from 3 to
6 days.
In a context of ageing population, where incidence of
HZ increases dramatically after 50 years of age, HZ im-
pact length of stay and contributes to demonstrating the
clinical and economic impact of HZ. The hospitalization
economic burden is only a part of the total cost of man-
agement of HZ.
Abbreviations
ATIH: Agence Technique de l’Information sur l’Hospitalisation; CCAM: French
Classification Of Medical Procedures or Classification Commune des Actes
Médicaux; CNIL: National commission for data processing and civil liberties;
COPD: Chronic Obstructive Pulmonary Disease; DAS: Secondary Associated
Diagnosis or Diagnostic Associé Significatif; DIM: Department Of Medical Data
or Département d’Information Médicale; DR: Associated Diagnosis or
Diagnostic Relié; ENCC: National study of costs or Echelle Nationale des Coûts
à Méthodologie Commune; HZ: Herpes Zoster; ICD-10: Xth Revision of the
International Classification of Diseases; INPES: French Institute for Health
Education and Prevention; INSEE: French Institute For Statistics And
Economic Studies; LOS: Length of Stay; PMSI-MCO: French Computerised
Hospital Database For Medicine, Surgery And Obstetrics or Programme de
Médicalisation des Systèmes d’Information-Médecine Chirurgie Obstétrique;
MDC: Major Diagnostic Category; PD: Principal Diagnosis or Diagnostic
Principal; PY: person-years; RSA: Discharge Summary or Résumé de Sortie
Anonyme; SSR: Recovery Center or Soin de Suite et de Réadaptation;
T2A: Prospective Payment or Tarification à l’Activité; USLD: Long-Term Unit
Care or Unité de Soins de Longue Durée; VZV: Varicella-Zoster Virus.
Competing interests
This study was supported by an unrestricted grant from SP MSD. Charles
Baptiste is an employee of Sanofi Pasteur. Cécile Blein is an employee of
HEVA, who were contracted by Sanofi Pasteur to participate in this study.
Alexandre Vainchtock is the CEO of HEVA who was contracted by Sanofi
Pasteur to participate in this study.
Blein et al. BMC Infectious Diseases  (2015) 15:350 Page 9 of 10
Gaetan Gavazzi has already acted as a consultant, orator or advisory board
for Pfizer/ BioMérieux, Sanofi-Pasteur MSD: Sanofi-Pasteur MSD, Pfizer,
ViforPharma,Novartis, AstraZeneca.
Gilles Berrut has already worked for Sanofi Pasteur MSD.
Marc Paccalin has never directly received fees from Sanofi Pasteur MSD.
Authors’ contributions
CB participated in the design of the study, performed the statistical analysis
and drafted the manuscript. GG, MP, BC, GB and AV participated in the
design and coordination and helped to draft the manuscript of the study. All
authors read and approved the final manuscript.
Acknowledgements
The authors kindly acknowledge SP MSD for its support in the analysis
conduct, the DIM physician, Dr. J. FERNANDEZ who brought his expertise in
the hospital coding management and Maëlle DELEGLISE, HEVA HEOR, for the
medical writing support.
Author details
1HEVA, Lyon, France. 2Université de Grenoble-Alpes et GREPI, clinique
universitaire de médecine gériatrique, CHU de Grenoble, la tronche, France.
3Geriatrics Department University Hospital La Milétrie, Poitiers, France. 4Sanofi
Pasteur MSD, Lyon, France. 5Hôpital Saint Jacques, CHU de Nantes, Nantes,
France.
Received: 24 November 2014 Accepted: 23 July 2015
References
1. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al.
Recommendations for the management of Herpes Zoster. Clin Infect Dis.
2007;44(Supplement 1):S1–S26.
2. Wallace MS, Oxman MN. Acute herpes zoster and postherpetic neuralgia.
Anesthesiology Clinics of North America. 1997;2(13):371–405.
3. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and
postherpetic neuralgia. Mayo Clin Proc Mayo Clin. 2009;84(3):274–80.
4. Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for
herpes zoster: population based case–control study. BMJ. 2014;348:g2911.
doi:10.1136/bmj.g2911.
5. Shingles (Herpes Zoster) Clinical Overview. Centers Dis. Control Prev. 2012. http://
www.cdc.gov/shingles/hcp/clinical-overview.html (assessed on 17 august 2015)
6. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A
vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N
Engl J Med. 2005;352(22):2271–84.
7. Nagasako EM, Johnson RW, Griffin DRJ, Dworkin RH. Rash severity in herpes
zoster: correlates and relationship to postherpetic neuralgia. J Am Acad
Dermatol. 2002;46(6):834–9.
8. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-
based study of the incidence and complication rates of herpes zoster before
zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.
9. Yawn BP, Wollan PC, St. Sauver JL, Butterfield LC. Herpes zoster Eye
complications: rates and trends. Mayo Clin Proc. 2013;88(6):562–70.
10. Schiffner-Rohe J, Jow S, Lilie HM, Köster I, Schubert I. Herpes zoster in Germany. A
retrospective analyse of SHL data. MMW Fortschr Med. 2010;151 Suppl 4:193–7.
11. Helgason S, Sigurdsson JA, Gudmundsson S. The clinical course of herpes
zoster: a prospective study in primary care. Eur J Gen Pr. 1996;2(1):12–6.
12. Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster
incidence across Europe: results from a systematic literature review. BMC Infect
Dis. 2013;13:170.
13. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and
complications of herpes zoster: towards a global perspective. BMJ Open.
2014;4:e004833. doi:10.1136/bmjopen-2014-004833.
14. Rimland D, Moanna A. Increasing incidence of herpes zoster among veterans.
Clinical Infectious Diseases. 2010;50:1000–5.
15. Yawn BP, Wollan PC, Kurland MJ, St. Sauver JL, Saddier P. Herpes zoster
recurrences more frequent than previously reported. Mayo Clin Proc.
2011;86(2):88–93.
16. Réseau Sentinelles. Bilan annuel 2009 - Rapport d’activité. Paris; 2009 déc.
17. Réseau Sentinelles. Bilan annuel 2010 - Rapport d’activité. Paris; 2010 déc.
18. Réseau Sentinelles. Bilan annuel 2011 - Rapport d’activité. Paris; 2011 déc.
19. Réseau Sentinelles. Bilan annuel 2012 - Rapport d’activité. Paris; 2012 déc.
20. Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, et al.
Herpes zoster: burden of disease in France. Vaccine. 2010;28(50):7933–8.
21. Riou C, Rouget F, Sinteff J, et al. Outil de contrôle d’exhaustivité des cas pour le
registre des malformations congénitales de Bretagne à partir des données PMSI.
Journées EMOIS Nancy. 2013
22. Buisson G. Redressement du Programme de médicalisation des systèmes
d’informations (PMSI). Direction de la recherche, des études, de l’évaluation et
des statistiques; 2005 Mar 1. Report No.: 80.
23. Haut conseil de la Santé Publique. Les systèmes d’information pour la santé
publique. November 2009. [http://www.ladocumentationfrancaise.fr/rapports-
publics/104000182/index.shtml] (Accessed august 2015).
24. Quantin C, Cottenet J, Vuagnat A, Benzenine E, Fresson J, Prunet C, et al.
Validité des données périnatales issues du pmsi: comparaison avec les
données de l’enquête nationale périnatale 2010. Rev Epidemiol Sante
Publique. 2013;61:S6.
25. Bernier M-O, Mezzarobba M, Maupu E, Caër-Lorho S, Brisse HJ, Laurier D, et al.
Role of French hospital claims databases from care units in epidemiological
studies: the example of the « Cohorte Enfant Scanner » study. Rev Epidemiol
Sante Publique. 2012;60(5):363–70.
26. Hafdi-Nejjari Z, Couris C-M, Schott A-M, Schot A-M, Perrot L, Bourgoin F, et al.
Role of hospital claims databases from care units for estimating thyroid cancer
incidence in the Rhône-Alpes region of France. Rev Epidemiol Sante Publique.
2006;54(5):391–8.
27. Yancik R, Ershler W, Satariano W, Hazzard W, et al. Comorbidity: the ultimate
geriatric syndrome: report of the National Institute on Aging Task Force on
Comorbidity. J Gerontol A Biol Sci Med Sci. 2007;62(3):275–80.
28. Castle SC, Uyemura K, Rafi A, Akande O, Makinodan T. Comorbidity is a better
predictor of impaired immunity than chronological age in older adults. J Am
Geriatr Soc. 2005;53:1565–9.
29. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for
herpes zoster? Lancet Infect Dis. 2004;4(1):26–33.
30. Yang YW, Chen YH, Wang KH, Wang CY, Lin HW. Risk of herpes zoster among
patients with chronic obstructive pulmonary disease: a population-based
study. CMAJ. 2011;183(5):E275–80.
31. Wu MY, Hsu YH, Su CL, Lin YF, Lin HW. Risk of herpes zoster in CKD: a
matched-cohort study based on administrative data. Am J Kidney Dis.
2012;60(4):548–52.
32. Kuo CC, Lee CT, Lee IM, Ho SC, Yang CY. Risk of herpes zoster in patients
treated with long-term hemodialysis: a matched cohort study. Am J Kidney
Dis. 2012;59(3):428–33.
33. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al.
Herpes zoster risk factors in a national cohort of veterans with rheumatoid
arthritis. Clin Infect Dis. 2009;48(10):1364–71.
34. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster
among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol.
2006;4(12):1483–90.
35. Guignard AP, Greenberg M, Lu C, Rosillon D, Vannappagari V. Risk of herpes
zoster among diabetics: a matched cohort study in a US insurance claim
database before introduction of vaccination, 1997–2006. Infection.
2014;42:729–35.
36. Cotton SJ, Belcher J, Rose P, Jagadeesan KS, Neal RD. The risk of a subsequent
cancer diagnosis after herpes zoster infection: primary care database study. Br J
Cancer. 2013;108(3):721–6.
37. Chiu HF, Chen BK, Yang CY. Herpes zoster and subsequent risk of cancer: a
population-based study. J Epidemiol. 2013;23(3):205–10.
38. Gil-Prieto R, San Martín M, de Andrés AL, Alvaro-Meca A, González A, de Miguel
AG. Herpes zoster hospitalizations of patients with chronic illnesses in Spain,
1998–2004. Vacunas. 2011;12(3):95–101.
39. Chang CM, Woo E, Yu YL, Huang CY, Chin D. Herpes zoster and its neurological
complications. Postgrad Med J. 1987;63(736):85–9.
40. Volpi A, Gross G, Hercogova J, Johnson RW. Current management of herpes
zoster: the European view. Am J Clin Dermatol. 2005;6(5):317–25.
41. Sawyer AR, Williams G. Misdiagnosis of burns: herpes zoster ophthalmicus. J Burn
Care Res. 2006;27(6):914–6.
42. Lin H-C, Chien C-W, Ho J-D. Herpes zoster ophthalmicus and the risk of stroke:
a population-based follow-up study. Neurology. 2010;74(10):792–7.
43. Gauthier A, Breuer J, Carrington D, Martin M, Rémy V. Epidemiology and cost of
herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol
Infect. 2009;137(1):38–47.
Blein et al. BMC Infectious Diseases  (2015) 15:350 Page 10 of 10
